
Newsroom
Press Room
-
PDF2020-04-16MMMM DD YYYYImportant Information on Plaquenil® and COVID-19
-
PDF2020-04-14MMMM DD YYYYSanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
-
PDF2018-12-28MMMM MM YYYYWhite particles found in Quadrivalent influenza vaccines are inert and non-toxic cellulose without concern on quality, safety and efficacy
-
PDF2018-10-01MMMM MM YYYYSanofi completes divestiture of Zentiva to Advent
-
PDF2018-09-28MMMM MM YYYYFDA approves Libtayo as first and only treatment for advanced cutaneous squamous cell carcinoma
-
PDF2018-09-15MMMM MM YYYYPositive Phase 3 results presented for Dupixent show significant improvement on multiple measures of disease sever
-
PDF2018-09-13MMMM MM YYYYSanofi to refocus two global business units
-
PDF2018-09-12MMMM MM YYYYFDA to review supplemental Biologics License Application for Praluent Injection as potential treatment
-
PDF2018-09-04MMMM MM YYYYSanofi reaches civil settlement with US SEC
-
PDF2018-09-03MMMM MM YYYYCablivi approved in Europe for adults with acquired thrombotic thrombocytopenic purpura
-
PDF2018-07-31MMMM MM YYYYQ2 2018 Performance Positions Sanofi for New Growth Phase
-
PDF2018-07-26MMMM MM YYYYSanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1<sup>st</sup>
-
PDF2018-07-29MMMM MM YYYYCHMP recommends approval of Cablivi
-
PDF2018-06-28MMMM MM YYYYSanofi and Advent finalize negotiations for the acquisition of Zentiva
-
PDF2018-06-19MMMM MM YYYYSanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer
-
PDF2018-06-13LLSanofi successfully prices USD 2 billion bond issue
-
PDF2018-06-11MMMM MM YYYYSanofi Launches Action 2018, a Worldwide Employee Stock Purchase Plan
-
PDF2018-06-04LLNew England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
-
PDF2018-05-21LLNew England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent improved moderate-to-severe
-
PDF2018-05-16LLDupixent<sup>®</sup> (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
SAHK.SA.18.06.0174/APR2019